Ovarian cancer is one of the most severe of oncological diseases. Inherited mutations in cancer susceptibility genes play a causal role in 5-10% of newly diagnosed tumours. BRCA1 and BRCA2 gene alterations are found in the majority of these cases. The aim of this study was to analyse the BRCA1 gene in the ovarian cancer risk group to characterize the spectrum of its mutations in the Czech Republic. Five overlapping fragments amplified on both genomic DNA and cDNA were used to screen for the whole protein-coding sequence of the BRCA1 gene. These fragments were analysed by the protein truncation test (PTT) and direct sequencing. Three inactivating mutations were identified in the group of 30 Czech ovarian cancer patients: the 5382insC mutation in two unrelated patients and a deletion of exons 21 and 22 in another patient. In addition, we have found an alternatively spliced product lacking exon 5 in two other unrelated patients. The 5382insC is the most frequent alteration of the BRCA1 gene in Central and Eastern Europe. The deletion of exons 21 and 22 affects the BRCT functional domain of the BRCA1 protein. Although large genomic rearragements are known to be relatively frequent in Western European populations, no analyses have been performed in our region yet.

Department of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University U Nemocnice 5 12853 Prague 2 Czech Republic

Zobrazit více v PubMed

Med Princ Pract. 2003 Jan-Mar;12(1):23-9 PubMed

Nat Genet. 1997 Nov;17(3):341-5 PubMed

Hum Mutat. 2004 Apr;23(4):397-8 PubMed

Acta Biochim Pol. 2002;49(2):351-6 PubMed

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5605-10 PubMed

Curr Opin Cell Biol. 2003 Jun;15(3):345-50 PubMed

Hum Mutat. 2001 Dec;18(6):545 PubMed

Neoplasma. 2003;50(4):246-50 PubMed

Ceska Gynekol. 2003 Jan;68(1):11-6 PubMed

Hum Mutat. 1993;2(4):245-8 PubMed

Science. 1994 Oct 7;266(5182):66-71 PubMed

Cas Lek Cesk. 2000 Oct 11;139(20):635-7 PubMed

Science. 1990 Dec 21;250(4988):1684-9 PubMed

Trends Biochem Sci. 2000 Oct;25(10):469-74 PubMed

Hum Mol Genet. 2001 Apr;10(7):705-13 PubMed

Endocr Relat Cancer. 1999 Dec;6(4):521-8 PubMed

Hum Genet. 2000 Oct;107(4):385-90 PubMed

Lancet. 1994 Mar 19;343(8899):692-5 PubMed

Am J Hum Genet. 2002 Apr;70(4):858-65 PubMed

JAMA. 1997 Oct 15;278(15):1242-50 PubMed

Lancet. 1996 Jun 15;347(9016):1643-5 PubMed

Nat Genet. 1995 Jun;10(2):208-12 PubMed

Hum Mutat. 2003 May;21(5):553-4 PubMed

Am J Hum Genet. 1996 Jan;58(1):42-51 PubMed

RNA. 1995 Jul;1(5):453-65 PubMed

Breast Cancer Res. 2003;5(6):R206-16 PubMed

High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer